Combination chemotherapy with bevacizumab and S-1 for elderly patients with metastatic colorectal cancer (BASIC trial)

M. Yoshida, K. Muro, A. Tsuji, Yasuo Hamamoto, T. Yoshino, K. Yoshida, K. Shirao, Y. Miyata, D. Takahari, T. Takahashi, A. Ohtsu

Research output: Contribution to journalArticle

14 Citations (Scopus)

Abstract

Background Chemotherapeutic regimens for elderly patients with metastatic colorectal cancer (mCRC), such as bevacizumab combined with 5-fluorouracil (5-FU) and leucovorin, often exclude oxaliplatin and irinotecan owing to the risk of toxicity. However, treatment with infusional 5-fluorouracil and leucovorin requires percutaneous port-catheter placement and other precautions, causing unnecessary stress for patients as well as healthcare workers. Methods We conducted a phase II study to evaluate the efficacy and safety of bevacizumab plus S-1 in elderly patients with previously untreated mCRC. Bevacizumab was given intravenously every two weeks, and S-1 was administered orally on days 1-28 of a 42-day cycle. The primary end-point was progression-free survival (PFS). The secondary end-points were time to treatment failure, response rate (RR), overall survival (OS), treatment completion status and safety. Results From October 2007 through March 2010, 56 patients were enroled. The median PFS was 9.9 months, the median OS was 25.0 months, and the RR was 57%. The main adverse events of grade 3 or higher were hypertension (11%), diarrhoea (9%) and neutropenia (7%). Conclusion Our results suggest that combination chemotherapy with S-1 and bevacizumab can be administered safely and continuously on an outpatient basis and is therapeutically effective in elderly patients with mCRC.

Original languageEnglish
Pages (from-to)935-941
Number of pages7
JournalEuropean Journal of Cancer
Volume51
Issue number8
DOIs
Publication statusPublished - 2015 May 1
Externally publishedYes

Fingerprint

Combination Drug Therapy
Colorectal Neoplasms
oxaliplatin
irinotecan
Leucovorin
Fluorouracil
Disease-Free Survival
Safety
Vascular Access Devices
Neutropenia
Treatment Failure
Diarrhea
Outpatients
Survival Rate
Bevacizumab
Hypertension
Delivery of Health Care
Survival
Therapeutics

Keywords

  • Bevacizuma b
  • Colorectal cancer
  • Elderly
  • S-1

ASJC Scopus subject areas

  • Oncology
  • Cancer Research

Cite this

Combination chemotherapy with bevacizumab and S-1 for elderly patients with metastatic colorectal cancer (BASIC trial). / Yoshida, M.; Muro, K.; Tsuji, A.; Hamamoto, Yasuo; Yoshino, T.; Yoshida, K.; Shirao, K.; Miyata, Y.; Takahari, D.; Takahashi, T.; Ohtsu, A.

In: European Journal of Cancer, Vol. 51, No. 8, 01.05.2015, p. 935-941.

Research output: Contribution to journalArticle

Yoshida, M, Muro, K, Tsuji, A, Hamamoto, Y, Yoshino, T, Yoshida, K, Shirao, K, Miyata, Y, Takahari, D, Takahashi, T & Ohtsu, A 2015, 'Combination chemotherapy with bevacizumab and S-1 for elderly patients with metastatic colorectal cancer (BASIC trial)', European Journal of Cancer, vol. 51, no. 8, pp. 935-941. https://doi.org/10.1016/j.ejca.2015.03.007
Yoshida, M. ; Muro, K. ; Tsuji, A. ; Hamamoto, Yasuo ; Yoshino, T. ; Yoshida, K. ; Shirao, K. ; Miyata, Y. ; Takahari, D. ; Takahashi, T. ; Ohtsu, A. / Combination chemotherapy with bevacizumab and S-1 for elderly patients with metastatic colorectal cancer (BASIC trial). In: European Journal of Cancer. 2015 ; Vol. 51, No. 8. pp. 935-941.
@article{72c9267016034a708f582bf705aaf58f,
title = "Combination chemotherapy with bevacizumab and S-1 for elderly patients with metastatic colorectal cancer (BASIC trial)",
abstract = "Background Chemotherapeutic regimens for elderly patients with metastatic colorectal cancer (mCRC), such as bevacizumab combined with 5-fluorouracil (5-FU) and leucovorin, often exclude oxaliplatin and irinotecan owing to the risk of toxicity. However, treatment with infusional 5-fluorouracil and leucovorin requires percutaneous port-catheter placement and other precautions, causing unnecessary stress for patients as well as healthcare workers. Methods We conducted a phase II study to evaluate the efficacy and safety of bevacizumab plus S-1 in elderly patients with previously untreated mCRC. Bevacizumab was given intravenously every two weeks, and S-1 was administered orally on days 1-28 of a 42-day cycle. The primary end-point was progression-free survival (PFS). The secondary end-points were time to treatment failure, response rate (RR), overall survival (OS), treatment completion status and safety. Results From October 2007 through March 2010, 56 patients were enroled. The median PFS was 9.9 months, the median OS was 25.0 months, and the RR was 57{\%}. The main adverse events of grade 3 or higher were hypertension (11{\%}), diarrhoea (9{\%}) and neutropenia (7{\%}). Conclusion Our results suggest that combination chemotherapy with S-1 and bevacizumab can be administered safely and continuously on an outpatient basis and is therapeutically effective in elderly patients with mCRC.",
keywords = "Bevacizuma b, Colorectal cancer, Elderly, S-1",
author = "M. Yoshida and K. Muro and A. Tsuji and Yasuo Hamamoto and T. Yoshino and K. Yoshida and K. Shirao and Y. Miyata and D. Takahari and T. Takahashi and A. Ohtsu",
year = "2015",
month = "5",
day = "1",
doi = "10.1016/j.ejca.2015.03.007",
language = "English",
volume = "51",
pages = "935--941",
journal = "European Journal of Cancer",
issn = "0959-8049",
publisher = "Elsevier Limited",
number = "8",

}

TY - JOUR

T1 - Combination chemotherapy with bevacizumab and S-1 for elderly patients with metastatic colorectal cancer (BASIC trial)

AU - Yoshida, M.

AU - Muro, K.

AU - Tsuji, A.

AU - Hamamoto, Yasuo

AU - Yoshino, T.

AU - Yoshida, K.

AU - Shirao, K.

AU - Miyata, Y.

AU - Takahari, D.

AU - Takahashi, T.

AU - Ohtsu, A.

PY - 2015/5/1

Y1 - 2015/5/1

N2 - Background Chemotherapeutic regimens for elderly patients with metastatic colorectal cancer (mCRC), such as bevacizumab combined with 5-fluorouracil (5-FU) and leucovorin, often exclude oxaliplatin and irinotecan owing to the risk of toxicity. However, treatment with infusional 5-fluorouracil and leucovorin requires percutaneous port-catheter placement and other precautions, causing unnecessary stress for patients as well as healthcare workers. Methods We conducted a phase II study to evaluate the efficacy and safety of bevacizumab plus S-1 in elderly patients with previously untreated mCRC. Bevacizumab was given intravenously every two weeks, and S-1 was administered orally on days 1-28 of a 42-day cycle. The primary end-point was progression-free survival (PFS). The secondary end-points were time to treatment failure, response rate (RR), overall survival (OS), treatment completion status and safety. Results From October 2007 through March 2010, 56 patients were enroled. The median PFS was 9.9 months, the median OS was 25.0 months, and the RR was 57%. The main adverse events of grade 3 or higher were hypertension (11%), diarrhoea (9%) and neutropenia (7%). Conclusion Our results suggest that combination chemotherapy with S-1 and bevacizumab can be administered safely and continuously on an outpatient basis and is therapeutically effective in elderly patients with mCRC.

AB - Background Chemotherapeutic regimens for elderly patients with metastatic colorectal cancer (mCRC), such as bevacizumab combined with 5-fluorouracil (5-FU) and leucovorin, often exclude oxaliplatin and irinotecan owing to the risk of toxicity. However, treatment with infusional 5-fluorouracil and leucovorin requires percutaneous port-catheter placement and other precautions, causing unnecessary stress for patients as well as healthcare workers. Methods We conducted a phase II study to evaluate the efficacy and safety of bevacizumab plus S-1 in elderly patients with previously untreated mCRC. Bevacizumab was given intravenously every two weeks, and S-1 was administered orally on days 1-28 of a 42-day cycle. The primary end-point was progression-free survival (PFS). The secondary end-points were time to treatment failure, response rate (RR), overall survival (OS), treatment completion status and safety. Results From October 2007 through March 2010, 56 patients were enroled. The median PFS was 9.9 months, the median OS was 25.0 months, and the RR was 57%. The main adverse events of grade 3 or higher were hypertension (11%), diarrhoea (9%) and neutropenia (7%). Conclusion Our results suggest that combination chemotherapy with S-1 and bevacizumab can be administered safely and continuously on an outpatient basis and is therapeutically effective in elderly patients with mCRC.

KW - Bevacizuma b

KW - Colorectal cancer

KW - Elderly

KW - S-1

UR - http://www.scopus.com/inward/record.url?scp=84928978561&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84928978561&partnerID=8YFLogxK

U2 - 10.1016/j.ejca.2015.03.007

DO - 10.1016/j.ejca.2015.03.007

M3 - Article

C2 - 25837882

AN - SCOPUS:84928978561

VL - 51

SP - 935

EP - 941

JO - European Journal of Cancer

JF - European Journal of Cancer

SN - 0959-8049

IS - 8

ER -